BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING AN INFECTIOUS DISEASE OR CANCER
Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.
1 - 109 . (canceled)
110 . A method for administering an effective amount of a pharmacologically active compound to a mammal to provide transmucosal absorption of a therapeutically effective amount of the active compound through the oral mucosa of the mammal to the systemic circulatory system of the mammal, comprising:
spraying the oral mucosa of the mammal with a propellant free buccal spray composition, containing a pharmacologically active compound dissolved in a pharmacologically acceptable solvent, comprising in weight percent of the composition:
an active compound in an amount between 0.001 and 60 percent by weight of the total composition comprising a monoclonal antibody, an anti-bacterial agent, an anti-parasitic agent, an agent for treating fungal infection, a vaccine, an antidote, an anti-malaria drug, hormone inhibitor, an immunoglobulin, a natural antibody, a natural toxin, a nucleoside, a recombinant human protein, a protein or peptide replacement or a mixture thereof; and
a polar solvent in an amount between 30 and 99.69 percent by weight of the total composition.
111 . The method of claim 110 , further comprising a flavoring agent in an amount between 0.1 and 10 percent by weight of the total composition.
112 . The method of claim 111 , wherein the active compound is selected from the group consisting of drotrecogin alfa, tifacogin or a pharmaceutically acceptable salt thereof.
113 . The method of claim 111 , wherein the polar solvent is present in an amount between 37 and 98.58 percent by weight of the total composition, the active compound is present in an amount between 0.005 and 55 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.5 and 8 percent by weight of the total composition.
114 . The method of claim 113 , wherein the polar solvent is present in an amount between 60.9 and 97.06 percent by weight of the total composition, the active compound is present in an amount between 0.01 and 40 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.75 and 7.5 percent by weight of the total composition.
115 . The method of claim 110 , wherein the polar solvent comprises a polyethylene glycol having a molecular weight between 400 and 1000, a C 2 to C 8 mono- and polyalcohol, or a C 7 to C 18 alcohol of linear or branched configuration.
116 . The method of claim 110 , wherein the polar solvent comprises aqueous polyethylene glycol.
117 . The method of claim 110 , wherein the polar solvent comprises aqueous ethanol.
118 . The method of claim 113 , wherein the flavoring agent comprises a synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavor, sweetener or a mixture thereof.
119 . The method of claim 111 , wherein the amount of the spray is predetermined.
120 . A method for administering an effective amount of a pharmacologically active compound to a mammal to provide transmucosal absorption of a therapeutically effective amount of the active compound through the oral mucosa of the mammal to the systemic circulatory system of the mammal, comprising:
spraying the oral mucosa of the mammal with a propellant free buccal spray composition, containing a pharmacologically active compound dissolved in a pharmacologically acceptable solvent, comprising in weight percent of the composition:
an active compound in an amount between 0.005 and 55 percent by weight of the total composition comprising a monoclonal antibody, an anti-bacterial agent, an anti-parasitic agent, an agent for treating fungal infection, a vaccine, an antidote, an anti-malaria drug, hormone inhibitor, an immunoglobulin, a natural antibody, a natural toxin, a nucleoside, recombinant human protein, a protein or peptide replacement or a mixture thereof, and
a non-polar solvent in an amount between 30 and 99.69 percent by weight of the total composition.
121 . The method of claim 120 , wherein the active compound is selected from the group consisting of drotrecogin alfa, tifacogin or a pharmaceutically acceptable salt thereof.
122 . The method according to claim 120 , further comprising a flavoring agent in an amount between 0.1 and 10 percent by weight of the total composition.
123 . The method according to claim 120 , wherein the solvent comprises a (C 2 -C 6 ) fatty acid (C 2 -C 6 ) ester, a C 7 -C 18 hydrocarbon of linear or branched configuration, a C 2 -C 6 alkanoyl ester, or a triglyceride of C 2 -C 6 carboxylic acid.
124 . The method according to claim 123 , wherein the solvent comprises one or more fatty acid esters.
125 . The method of claim 122 , wherein the flavoring agent comprises a synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavor, sweetener or a mixture thereof.
126 . The method of claim 122 , wherein the amount of the spray is predetermined.
127 . A method for administering an effective amount of a pharmacologically active compound to a mammal to provide transmucosal absorption of a therapeutically effective amount of the active compound through the oral mucosa of the mammal to the systemic circulatory system of the mammal, comprising:
spraying the oral mucosa of the mammal with a propellant free buccal spray composition, containing a pharmacologically active compound dissolved in a pharmacologically acceptable solvent, comprising in weight percent of the composition:
an active compound in an amount between 0.001 and 60 percent by weight of the total composition, wherein the active compound comprises insulin;
a polar solvent in an amount between 10 and 40 percent by weight of the total composition, wherein the polar solvent is selected from the group consisting of ethanol and propylene glycol; and
water.